Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat.com A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. Article Published: 1/14/2026. 
Key Points - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is always a good time to revisit ana initial public offering (IPO) calendar. Almost every week, companies go public, and a handful offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors shouldn't dismiss every newly listed stock — some that recently went public may merit a place in buy-and-hold portfolios. Former Trump Adviser Reveals Administration's Shocking Wealth Initiative
President Donald Trump just signed a mandate that promises to redistribute wealth from Wall Street to everyday Americans. And a small group of Americans is already collecting their share of up to $68 billion that's up for grabs. This is money that must be paid out by federal law. Click here to discover how to claim your share. One biotechnology company in the healthcare sector that just went public could be one of those exceptions. Last Year's IPO Success Stories Last year illustrates why IPOs shouldn't be automatically written off by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its IPO. Short-term traders capitalized on a nearly 359% gain within the first 30 days of listing, while longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), counter the notion that IPOs are only high-risk startups. The medical products and services provider — founded in 1966 and publicly debuted in December 2025 — now has a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD) — known for its ubiquitous packages of bacon — waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals that began trading on Jan. 9, 2026, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals — a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing harm to surrounding healthy tissue compared with some conventional treatments. Industry consultancy Grand View Research estimated the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it will reach almost $35 billion by 2030, a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the predominant player — a meaningful point for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Biotechnology Wall Street expects biotech IPOs to rebound in 2026 after funding cuts under the previous administration slowed healthcare listings in 2025. Aktis Oncology debuted on Nasdaq on Jan. 9 as the first biotech IPO of 2026, raising $318 million in IPO proceeds and giving it an implied market cap of roughly $3.34 billion. According to the company's prospectus, the executive team includes experienced drug development, regulatory and commercialization professionals, with management having participated in bringing 14 currently FDA-approved products to market. Technically, Aktis develops targeted alpha radiopharmaceuticals — a new class of precision cancer drugs that use proprietary targeting technology to attack solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Notably, Aktis is a clinical-stage, pre-revenue company. That did not prevent it from attracting significant interest from Eli Lilly (NYSE: LLY), which anchored the IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares as part of the IPO. This investment builds on a 2024 partnership in which Aktis received $60 million in cash and an equity investment from Eli Lilly, plus potential milestone payments that could exceed $1 billion to develop tumor-targeting radiopharmaceuticals. The significance of Lilly's backing should not be understated. At roughly $1.01 trillion, Eli Lilly ranks among the largest Big Pharma companies by market cap; its net income jumped nearly 109% year-over-year from 2023 to 2024. That momentum is expected to continue when Eli Lilly reports Q4 and 2025 full-year financials on Feb. 5. Between its equity stake and the recent $100 million purchase of AKTS shares, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
| 
